OPKO Health (NASDAQ:OPK) Posts Earnings Results

OPKO Health (NASDAQ:OPK) announced its earnings results on Thursday. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09, Zacks reports. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The company had revenue of $183.60 million for the quarter, compared to analyst estimates of $155.42 million.

OPKO Health Stock Down 1.8 %

OPK stock opened at $1.63 on Friday. The firm has a market cap of $1.11 billion, a price-to-earnings ratio of -8.58 and a beta of 1.63. OPKO Health has a 1-year low of $0.86 and a 1-year high of $1.76. The firm has a fifty day moving average price of $1.55 and a two-hundred day moving average price of $1.55. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.

Analyst Upgrades and Downgrades

A number of research analysts have commented on OPK shares. Barrington Research reiterated an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research note on Friday, November 8th. HC Wainwright reiterated a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Wednesday, January 8th. Finally, StockNews.com cut OPKO Health from a “hold” rating to a “sell” rating in a research note on Wednesday, January 15th.

Insider Transactions at OPKO Health

In related news, CEO Phillip Md Et Al Frost purchased 47,537 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The shares were acquired at an average price of $1.47 per share, with a total value of $69,879.39. Following the acquisition, the chief executive officer now owns 213,234,014 shares in the company, valued at approximately $313,454,000.58. This trade represents a 0.02 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last three months, insiders have acquired 1,322,537 shares of company stock worth $2,009,129. 47.26% of the stock is currently owned by insiders.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.